CD10 expression in diffuse large B-cell lymphomas does not influence survival

Virchows Archiv

Volumn 445, Issue 6, 2004, Pages 545-551

  Fabiani, Bettina ^a   Delmer, Alain ^b   Lepage, Eric ^c   Guettier, Catherine ^d   Petrella, Tony ^e   Brière, Josette ^f   Penny, Anne Marie ^g   Copin, Marie Christine ^h   Diebold, Jacques ^b   Reyes, Felix ^c   Gaulard, Philippe ^c   Molina, Thierry J ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔTEL DIEU   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical pathology; Lymphoma; Tumor marker

Indexed keywords

BLEOMYCIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; B CELL LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOBLAST; IMMUNOBLASTIC LYMPHOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORPHOLOGY; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE;

EID: 19944429950     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-004-1129-7     Document Type: Review

References (29)

1. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921-1925
2. Almasri NM, Iturraspe JA, Braylan RC (1998) CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Arch Pathol Lab Med 122:539-544
3. Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen. A GELA cohort study on 2837 patients. Blood 103:1222-1228
4. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack A (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143
5. Chang CC, Cleveland RP, Perkins SL (2002) CD10 expression and survival. Am J Clin Pathol 117:660-661
6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
7. Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325-334
8. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101:78-84
9. Dogan A, Bagdi E, Munson P, Isaacson PG (2000) CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846-852
10. Fang JM, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Variakojis D (1999) CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol 12:295-300
11. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251
12. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin F, Hermine O, Reyes F (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479
13. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller- Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
14. Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M, Suzuki H, Oyama A, Kodera Y, Ueda R, Morishima Y, Naka-mura S, Seto M (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5-with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441-1447
15. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265-272
16. Hojo H, Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Sato M, Shirakawa A, Abe M (2002) Analysis of immunoglobulin VH genes in CD10-positive diffuse large B-cell lymphoma. Pathol Int 52:586-594
17. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534
18. Jaffee ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
19. Kaplan EMP (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457
20. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD (1997) Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90:4078-4091
21. Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G, Gisselbrecht C, Reyes F, Gaulard P (2002) p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13:1108-1115
22. McCluggage WG, Catherwood M, Alexander HD, McBride HA, Smith ME, Morris TC (2002) Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology 41:414-420
23. Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S, Suzumiya J, Podack ER, Kikuchi M (2001) CD10 and Bc110 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 39:156-162
24. Ree HJ, Yang WI, Kim CW, Huh J, Lee SS, Cho EY, Ko YH, Charney D (2001) Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol 32:954-962
25. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947
26. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 102:4284-4289
27. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG (2001) The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol 115:582-588
28. Xu Y, McKenna RW, Molberg KH, Kroft SH (2001) Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 116:183-190
29. Xu Y, McKenna RW, Kroft SH (2002) Comparison of multi-parameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas. Mod Pathol 15:413-419